Capricor Therapeutics Inc... (CAPR)
| Bid | 8.8 |
| Market Cap | 422.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.15 |
| PE Ratio (ttm) | -8.04 |
| Forward PE | -18.15 |
| Analyst | Buy |
| Ask | 9.25 |
| Volume | 1,333,865 |
| Avg. Volume (20D) | 1,204,416 |
| Open | 9.27 |
| Previous Close | 9.74 |
| Day's Range | 8.69 - 9.43 |
| 52-Week Range | 3.52 - 23.40 |
| Beta | 4.11 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph...
Analyst Forecast
According to 7 analyst ratings, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 251.35% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call TranscriptCapricor Therapeutics, Inc. (NASDAQ:CAPR ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Office...
1 month ago · seekingalpha.com
Capricor: Further Value Unlocked With Priority Review Of DeramiocelCapricor Therapeutics, Inc.'s Deramiocel received FDA Priority Review with a PDUFA target date of August 31, 2025, for the treatment of patients with DMD Cardiomyopathy. Deramiocel could become the fi...
1 month ago · seekingalpha.com
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE DataCapricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was demonstrate...
